MX2017016835A - Métodos de tratamiento de trastornos autoinmunitarios y aloinmunitarios. - Google Patents

Métodos de tratamiento de trastornos autoinmunitarios y aloinmunitarios.

Info

Publication number
MX2017016835A
MX2017016835A MX2017016835A MX2017016835A MX2017016835A MX 2017016835 A MX2017016835 A MX 2017016835A MX 2017016835 A MX2017016835 A MX 2017016835A MX 2017016835 A MX2017016835 A MX 2017016835A MX 2017016835 A MX2017016835 A MX 2017016835A
Authority
MX
Mexico
Prior art keywords
methods
individual
treating autoimmune
alloimmune
present disclosure
Prior art date
Application number
MX2017016835A
Other languages
English (en)
Spanish (es)
Inventor
Panicker Sandip
Parry Graham
A Nikitin Pavel
Original Assignee
Bioverativ Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Usa Inc filed Critical Bioverativ Usa Inc
Publication of MX2017016835A publication Critical patent/MX2017016835A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2017016835A 2015-06-26 2016-06-23 Métodos de tratamiento de trastornos autoinmunitarios y aloinmunitarios. MX2017016835A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562185362P 2015-06-26 2015-06-26
PCT/US2016/039087 WO2016210172A1 (en) 2015-06-26 2016-06-23 Methods of treating autoimmune and alloimmune disorders

Publications (1)

Publication Number Publication Date
MX2017016835A true MX2017016835A (es) 2018-08-01

Family

ID=57585852

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017016835A MX2017016835A (es) 2015-06-26 2016-06-23 Métodos de tratamiento de trastornos autoinmunitarios y aloinmunitarios.
MX2023002021A MX2023002021A (es) 2015-06-26 2017-12-19 Anticuerpos de union al componente de complemento 1 c1s para usarse en el tratamiento de trastornos autoinmune y aloinmune.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023002021A MX2023002021A (es) 2015-06-26 2017-12-19 Anticuerpos de union al componente de complemento 1 c1s para usarse en el tratamiento de trastornos autoinmune y aloinmune.

Country Status (12)

Country Link
US (3) US20180169240A1 (cg-RX-API-DMAC7.html)
EP (1) EP3313417A4 (cg-RX-API-DMAC7.html)
JP (1) JP6963509B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180020296A (cg-RX-API-DMAC7.html)
CN (1) CN108348600A (cg-RX-API-DMAC7.html)
AU (2) AU2016282782A1 (cg-RX-API-DMAC7.html)
CA (1) CA2990662A1 (cg-RX-API-DMAC7.html)
EA (1) EA038567B1 (cg-RX-API-DMAC7.html)
HK (1) HK1254030A1 (cg-RX-API-DMAC7.html)
IL (1) IL256424B2 (cg-RX-API-DMAC7.html)
MX (2) MX2017016835A (cg-RX-API-DMAC7.html)
WO (1) WO2016210172A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2912065A4 (en) 2012-10-25 2016-10-19 True North Therapeutics Inc ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF
RS63212B1 (sr) 2012-11-02 2022-06-30 Bioverativ Usa Inc Antikomplementna c1s antitela i njihove primene
HK1259251A1 (zh) 2015-04-06 2019-11-29 Bioverativ Usa Inc. 人源化抗c1s抗体及其使用方法
DK3448419T5 (da) * 2016-04-29 2024-09-09 Pfizer Interferon-beta-antistoffer og anvendelser deraf
EP3525583B8 (en) 2016-10-12 2025-09-10 Bioverativ USA Inc. Anti-c1s antibodies and methods of use thereof
JP7731196B2 (ja) 2017-11-14 2025-08-29 中外製薬株式会社 抗Ｃ１ｓ抗体および使用方法
WO2020230834A1 (en) 2019-05-15 2020-11-19 Chugai Seiyaku Kabushiki Kaisha An antigen-binding molecule, a pharmaceutical composition, and a method
WO2021075479A1 (en) * 2019-10-16 2021-04-22 Chugai Seiyaku Kabushiki Kaisha An antibody, a pharmaceutical composition, and a method
CN116724236A (zh) * 2020-08-06 2023-09-08 美国比奥维拉迪维股份有限公司 患有补体介导的疾病的受试者中的炎性细胞因子和疲劳
EP4337332A2 (en) 2021-07-13 2024-03-20 Mabwell Therapeutics Inc. Anti-c1s antibodies and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001013945A1 (en) * 1999-08-23 2001-03-01 Biocrystal Ltd. Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis
ES2614274T3 (es) * 2002-09-06 2017-05-30 Alexion Pharmaceuticals, Inc. Procedimiento de tratamiento de asma usando anticuerpos frente al componente de complemento C5
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
WO2009132058A2 (en) * 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
CN102597005A (zh) * 2009-06-23 2012-07-18 阿雷克森制药公司 与补体蛋白质结合的双特异性抗体
EP2912065A4 (en) * 2012-10-25 2016-10-19 True North Therapeutics Inc ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF
RS63212B1 (sr) * 2012-11-02 2022-06-30 Bioverativ Usa Inc Antikomplementna c1s antitela i njihove primene

Also Published As

Publication number Publication date
US20220249664A1 (en) 2022-08-11
MX2023002021A (es) 2023-03-15
NZ738570A (en) 2025-05-02
EA201890106A1 (ru) 2018-05-31
US20180169240A1 (en) 2018-06-21
IL256424B1 (en) 2024-05-01
WO2016210172A1 (en) 2016-12-29
AU2022215307B2 (en) 2025-09-04
US20250295768A1 (en) 2025-09-25
EA038567B1 (ru) 2021-09-15
EP3313417A1 (en) 2018-05-02
BR112017027578A2 (pt) 2018-08-28
JP6963509B2 (ja) 2021-11-10
EP3313417A4 (en) 2019-06-12
IL256424B2 (en) 2024-09-01
KR20180020296A (ko) 2018-02-27
CA2990662A1 (en) 2016-12-29
CN108348600A (zh) 2018-07-31
IL256424A (en) 2018-02-28
JP2018526330A (ja) 2018-09-13
HK1254030A1 (zh) 2019-07-12
AU2016282782A1 (en) 2018-01-18
AU2022215307A1 (en) 2022-09-08

Similar Documents

Publication Publication Date Title
MX2023002021A (es) Anticuerpos de union al componente de complemento 1 c1s para usarse en el tratamiento de trastornos autoinmune y aloinmune.
MX2017005751A (es) Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
MX364886B (es) Lente oftálmica con sistema microfluídico.
EP4556576A3 (en) Methods to diagnose and treat acute respiratory infections
MX2017015758A (es) Componente de dispositivo, dispositivo, y metodo para purificar y ensayar biomoleculas de muestras biologicas.
EA201691683A1 (ru) Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме
PH12017502222B1 (en) Lag-3-binding molecules and methods of use thereof
EP2959280A4 (en) METHOD FOR LANGUAGE DECODING OF THE BRAIN AND SYSTEMS FOR CARRYING OUT THEREOF
MX2017001138A (es) Metodo.
WO2013142796A3 (en) Methods of treatments using ctla4 antibodies
MX368725B (es) Sistema cerrado integrado de extraccion de linea intravenosa.
HK1250752A1 (zh) 治疗骨髓增生性障碍的方法
WO2014169226A3 (en) Methods of diagnosing and treating chronic pain
MX2019009546A (es) Anticuerpos anti-factor d y uso de los mismos.
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
ZA201800498B (en) Anti¿pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
EA201691647A1 (ru) Способы кратковременного и долгосрочного лечения зависимости от лекарственных средств
EP3452825A4 (en) SYSTEM AND METHOD FOR DIFFERENTIATING BLOOD COMPONENTS
MX2019011252A (es) Anticuerpos anti-c5a y usos de los mismos.
EP4465017A3 (en) System for determining the amount of hemoglobin in a plasma fraction
EP3297703A4 (en) PHOTOTHERAPY SYSTEM AND METHOD FOR PREVENTING OR TREATING CARBON MONOXIDE POISONING
MX2017016337A (es) Tratamiento de carcinoma de linea media nut.
MX2015016844A (es) Marcador para trastornos de la esfingomielinasa acida y sus usos.
FR3029016B1 (fr) Procede d'enrichissement d'une electrode d'un dispositif electrochimique en espece ionique.